Talacotuzumab

A4DAB252 | Cancer | Phase-II

Target IL3RA/CD123

Isotype / Subclass G1 / IgG1/2

Company

CSL Janssen Biotech

Clinical Status Phase-II

Format Whole mAb

Synonyms

CSL-362 CSL362 CSL 362 JNJ 473 JNJ473 JNJ473 JNJ 56022473 JNJ56022473 JNJ-56022473

pH Formulation —

IMGT PubChem (381128089) PubChem (404719346) PubChem (404772246) PubChem (472419168) PubChem (476262729) PubChem (476269337) PubChem (498150096) Thera-SAbDab YAbS

Avg A4D Score

-0.7023

Score Range

-0.7 to -0.7

Structures

2

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB252_4jzj_A_B	4jzj	100%	-0.6999	6.5	9.0	-0.258	-0.7616
A4DAB252_4jzj_H_L	4jzj	100%	-0.7047	6.5	4.0	-0.3218	-0.7579

Talacotuzumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2